Walmsley Sharon
Department of Medicine, University of Toronto, University Health Network, Immunodeficiency Clinic, Toronto, Ontario M5G2C4, Canada.
Curr Opin HIV AIDS. 2008 Nov;3(6):647-52. doi: 10.1097/COH.0b013e3283136c9b.
The availability of new drugs in existing classes and new drugs in new classes has enabled better management of the treatment-experienced patient. This review will highlight the advances in the field and the new goals of therapy for this patient population.
The treatment-experienced patient on a failing regimen should receive a new combination of at least two, and ideally three, new agents that includes a drug within a new class. The goal of therapy is suppression of viral replication to less than 50 copies/ml. The new protease inhibitors with activity against strains with resistance to earlier members of the class are an important backbone to the new therapy given their high barrier to resistance.
The treatment-experienced patient can now be successfully managed with new agents and new classes of antiviral agents.
现有药物类别中的新药以及新药物类别的出现，使得对有治疗经验的患者能够进行更好的管理。本综述将重点介绍该领域的进展以及针对这一患者群体的新治疗目标。
采用失败治疗方案的有治疗经验的患者应接受至少两种（理想情况下为三种）新药物的新组合，其中包括一种新药物类别中的药物。治疗目标是将病毒复制抑制至低于50拷贝/毫升。对该类别早期成员耐药的菌株具有活性的新型蛋白酶抑制剂，因其高耐药屏障，是新治疗方案的重要基础。
现在可以使用新药物和新类别的抗病毒药物成功管理有治疗经验的患者。
Zotero 插件